{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:52:29Z","timestamp":1781635949075,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neddylation is a post-translational modification suppressed by the endogenous inhibitor NUB1, and its dysregulation in rheumatoid arthritis (RA) promotes inflammation and NF-\u03baB activation.  NUB1 expression in RA and osteoarthritis (OA) synovium and mechanisms underlying defective NUB1 induction in RA fibroblast-like synoviocytes (FLS)\u00a0were evaluated. NEDD8 and IL-6 protein expression was increased and NUB1 was reduced in RA synovium compared with OA tissue, with significant differences in the lining region that correlated with higher cytokine expression and NF-kB translocation. IL-1\u03b2\u2013induced NUB1 induction was impaired in RA FLS at both the mRNA and protein levels. To evaluate the mechanism, we assessed mRNA stability using actinomycin D, examined the role of SNHG12 by siRNA knockdown, analyzed MAP kinase signaling, and measured NUB1 promoter activity with a luciferase reporter assay.\u00a0None could explain the reduced induction observed in RA FLS. Treatment with the DNA methylation inhibitor 5-azacytidine and the histone methylation inhibitor EPZ6438 partially reversed the difference in NUB1 induction, whereas the histone deacetylase inhibitors ITF2375 and MS275 eliminated it. Therefore, defective NUB1 induction in RA FLS is related to the aberrant epigenetic landscape in RA FLS and is associated with increased neddylation and increased IL-6 expression in rheumatoid synovium. Overcoming increased neddylation in RA represents a novel therapeutic approach.<\/jats:p>","DOI":"10.1038\/s41598-026-38420-y","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:25:19Z","timestamp":1770701119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Altered fibroblast-like synoviocyte epigenetics is responsible for deficient NUB1 expression in rheumatoid arthritis"],"prefix":"10.1038","volume":"16","author":[{"given":"Yosuke","family":"Ono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla R. L.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Firestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"38420_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMra2103726","volume":"388","author":"EM Gravallese","year":"2023","unstructured":"Gravallese, E. M. & Firestein, G. S. Rheumatoid Arthritis - Common Origins, divergent mechanisms. N Engl. J. Med. 388, 529\u2013542 (2023).","journal-title":"N Engl. J. Med."},{"key":"38420_CR2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023\u20132038 (2016).","journal-title":"Lancet"},{"key":"38420_CR3","doi-asserted-by":"publisher","first-page":"e001235","DOI":"10.1136\/rmdopen-2020-001235","volume":"7","author":"TR Riley","year":"2021","unstructured":"Riley, T. R. & George, M. D. Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD Open. 7, e001235 (2021).","journal-title":"RMD Open."},{"key":"38420_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40744-023-00571-z","volume":"10","author":"BJM Bergmans","year":"2023","unstructured":"Bergmans, B. J. M. et al. Infections in biological and targeted synthetic drug use in rheumatoid arthritis: where do we stand? A scoping review and Meta-analysis. Rheumatol. Ther. 10, 1147\u20131165 (2023).","journal-title":"Rheumatol. Ther."},{"key":"38420_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","volume":"16","author":"G Nygaard","year":"2020","unstructured":"Nygaard, G. & Firestein, G. S. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat. Rev. Rheumatol. 16, 316\u2013333 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"38420_CR6","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes, I. B. & Schett, G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389, 2328\u20132337 (2017).","journal-title":"Lancet"},{"key":"38420_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrrheum.2012.190","volume":"9","author":"N Bottini","year":"2013","unstructured":"Bottini, N. & Firestein, G. S. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat. Rev. Rheumatol. 9, 24\u201333 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"38420_CR8","doi-asserted-by":"publisher","first-page":"890121","DOI":"10.3389\/fcell.2022.890121","volume":"10","author":"J Zhu","year":"2022","unstructured":"Zhu, J., Chu, F. & Zhang, M. et. Al. Association between neddylation and immune response. Front. Cell. Dev. Biol. 10, 890121 (2022).","journal-title":"Front. Cell. Dev. Biol."},{"key":"38420_CR9","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.2174\/13816128113199990300","volume":"19","author":"Y Zhao","year":"2013","unstructured":"Zhao, Y. et al. Cullin-RING ligases as attractive anti-cancer targets. Curr. Pharm. Des. 19, 3215\u20133225 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"38420_CR10","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/art.42856","volume":"76","author":"S Sendo","year":"2024","unstructured":"Sendo, S. et al. Dysregulated NUB1 and neddylation enhances rheumatoid arthritis Fibroblast-Like synoviocyte inflammatory responses. Arthritis Rheumatol. 76, 1252\u20131262 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"38420_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.11.006","volume":"340","author":"W Jiang","year":"2022","unstructured":"Jiang, W. et al. SNHG12 regulates biological behaviors of ox-LDL-induced HA-VSMCs through upregulation of SPRY2 and NUB1. Atherosclerosis 340, 1\u201311 (2022).","journal-title":"Atherosclerosis"},{"key":"38420_CR12","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.4049\/jimmunol.1202572","volume":"190","author":"K Nakano","year":"2013","unstructured":"Nakano, K., Boyle, D. L. & Firestein, G. S. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J. Immunol. 190, 1297\u20131303 (2013).","journal-title":"J. Immunol."},{"key":"38420_CR13","doi-asserted-by":"publisher","first-page":"e0304530","DOI":"10.1371\/journal.pone.0304530","volume":"19","author":"H Lee","year":"2024","unstructured":"Lee, H. et al. Joint-specific regulation of homeobox D10 expression in rheumatoid arthritis fibroblast-like synoviocytes. PLoS One. 19, e0304530 (2024).","journal-title":"PLoS One"},{"key":"38420_CR14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/gene.2011.45","volume":"12","author":"E Karouzakis","year":"2011","unstructured":"Karouzakis, E. et al. DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts. Genes Immun. 12, 643\u2013652 (2011).","journal-title":"Genes Immun."},{"key":"38420_CR15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/sj.bjc.6605574","volume":"102","author":"T Hosono","year":"2010","unstructured":"Hosono, T., Tanaka, T., Tanji, K., Nakatani, T. & Kamitani, T. NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation. Br. J. Cancer. 102, 873\u2013882 (2010).","journal-title":"Br. J. Cancer"},{"key":"38420_CR16","doi-asserted-by":"publisher","first-page":"153002","DOI":"10.1016\/j.prp.2020.153002","volume":"216","author":"D Zhang","year":"2020","unstructured":"Zhang, D. et al. Overexpression of negative regulator of ubiquitin-like proteins 1 (NUB1) inhibits proliferation and invasion of gastric cancer cells through upregulation of p27Kip1 and Inhibition of epithelial-mesenchymal transition. Pathol. Res. Pract. 216, 153002 (2020).","journal-title":"Pathol. Res. Pract."},{"key":"38420_CR17","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.3390\/cells10092176","volume":"10","author":"M Arshad","year":"2021","unstructured":"Arshad, M. et al. NUB1 and FAT10 proteins as potential novel biomarkers in cancer: A translational perspective. Cells 10, 2176 (2021).","journal-title":"Cells"},{"key":"38420_CR18","doi-asserted-by":"publisher","first-page":"20603","DOI":"10.1074\/jbc.M100920200","volume":"276","author":"K Kito","year":"2001","unstructured":"Kito, K., Yeh, E. T. & Kamitani, T. NUB1, a NEDD8-interacting protein, is induced by interferon and down-regulates the NEDD8 expression. J. Biol. Chem. 276, 20603\u201320609 (2001).","journal-title":"J. Biol. Chem."},{"key":"38420_CR19","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/s41467-018-04310-9","volume":"9","author":"R Ai","year":"2018","unstructured":"Ai, R. et al. Comprehensive epigenetic landscape of rheumatoid arthritis fibroblast-like synoviocytes. Nat. Commun. 9:1921(2018).","journal-title":"Nat. Commun."},{"key":"38420_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cell.2014.02.009","volume":"157","author":"M Levine","year":"2014","unstructured":"Levine, M., Cattoglio, C. & Tjian, R. Looping back to leap forward: transcription enters a new era. Cell 157, 13\u201325 (2014).","journal-title":"Cell"},{"key":"38420_CR21","doi-asserted-by":"crossref","unstructured":"Bonev, B. & Cavalli, G. Organization and function of the 3D genome. Nat. Rev. Genet. 17, 661\u2013678 (2016).","DOI":"10.1038\/nrg.2016.112"},{"key":"38420_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrg3207","volume":"13","author":"F Spitz","year":"2012","unstructured":"Spitz, F. & Furlong, E. E. Transcription factors: from enhancer binding to developmental control. Nat. Rev. Genet. 13, 613\u2013626 (2012).","journal-title":"Nat. Rev. Genet."},{"key":"38420_CR23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","volume":"5","author":"M Dokmanovic","year":"2007","unstructured":"Dokmanovic, M., Clarke, C. & Marks, P. A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5, 981\u2013989 (2007).","journal-title":"Mol. Cancer Res."},{"key":"38420_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd1930","volume":"5","author":"CB Yoo","year":"2006","unstructured":"Yoo, C. B. & Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5, 37\u201350 (2006).","journal-title":"Nat. Rev. Drug Discov"},{"key":"38420_CR25","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 rheumatoid arthritis classification criteria: an American college of Rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 62, 2569\u20132581 (2010).","journal-title":"Arthritis Rheum."},{"key":"38420_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/art.1780340502","volume":"34","author":"R Altman","year":"1991","unstructured":"Altman, R. et al. The American college of rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 34, 505\u2013514 (1991).","journal-title":"Arthritis Rheum."},{"key":"38420_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr2.11093","volume":"1","author":"D Hammaker","year":"2019","unstructured":"Hammaker, D. et al. Joint Location-Specific JAK-STAT signaling in rheumatoid arthritis Fibroblast-like synoviocytes. ACR Open. Rheumatol. 1, 640\u2013648 (2019).","journal-title":"ACR Open. Rheumatol."},{"key":"38420_CR28","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","volume":"13","author":"SK Knutson","year":"2014","unstructured":"Knutson, S. K. et al. Selective Inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 13, 842\u2013854 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"38420_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/acr2.11384","volume":"4","author":"C Ansalone","year":"2022","unstructured":"Ansalone, C. et al. Caspase-8 variant G regulates rheumatoid arthritis Fibroblast-Like synoviocyte aggressive behavior. ACR Open. Rheumatol. 4, 288\u2013299 (2022).","journal-title":"ACR Open. Rheumatol."},{"key":"38420_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2559.2006.02508.x","volume":"49","author":"V Krenn","year":"2006","unstructured":"Krenn, V. et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology 49, 358\u2013364 (2006).","journal-title":"Histopathology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38420-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38420-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38420-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:59:39Z","timestamp":1781632779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38420-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38420"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38420-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by Human Research Protection Program, and all patients provided informed consent (Protocol #14\u20130175). Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"8128"}}